Somamers

The firm is using collaborations to access the large, diverse cohorts it needs to support its goal of commercializing its SomaScan system as a clinical platform.

The companies will use Somalogic's SomaScan proteomic platform to measure levels of as many as 5,000 proteins in up to 40,000 of DeCode's patient samples.

Backed by €19 million in EU funding, the initiative, called BigData@Heart, will create a research platform that could change the way cardiovascular diseases are diagnosed and treated.

Under the agreement, BMS has access to the 1,310 reagents in the public version of SomaLogic's SOMAscan assay along with a number of custom-developed reagents.

Proteomics diagnostics firm Somalogic reported data this week supporting the utility of its blood-based 13-protein panel for the detection of malignant mesothelioma.

By Adam Bonislawski
Somalogic last week published in PLoS One a study offering the first data on use of its aptamer-based Somascan platform in tissue samples.

SomaLogic will provide New England Biolabs with protein-binding reagents for use in NEB's nucleic acid amplification and PCR products.

SomaLogic will supply NEB with certain of its SomaMers technology to be incorporated into NEB's products as reversible inhibitors of thermally active DNA polymerases used in PCR.

Pages

NPR reports that researchers in Italy are testing a gene drive aimed at controlling mosquito populations.

Researchers may experience the effects of the government shutdown for a while, the Los Angeles Times reports.

A new study finds that the majority of patients at a Tijuana clinic received a diagnosis after first-line genome sequencing, the San Diego Union-Tribune reports.

In Genome Biology this week: post-transcriptional modification-based stratification of glioblastoma, single-cell analysis of gene expression and methylation in human iPSCs, and more.